The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the world. Now, the pharma giant wants to reinvest its success with weight-loss ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...

CardCash.com to Offer Cost-Effective Solutions for High-Demand GLP-1 Medications as Prescription Drug Market Grows SCHAUMBURG, IL, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Giftify, Inc. (NASDAQ:GIFT) (the "C ...

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

The FDA has said it has agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli Lilly's diabetes and obesity drug tirzepatide. The US ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

(Reuters) - Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage ...

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug. Kisunla (donanemab) is the second in a new generation of ...